On December 26, 2013, Weichai Motors held a press conference for its “Letters to Ingenuity†brand in Beijing. General Manager Ye Weichai of Weichai Motor Co., Ltd. introduced the planning of Weichai for the next three years. Weichai Yingzhi will launch several models of the city's SUVs, high-end pickups, MPVs, and off-road SUVs.
According to the information released by Weichai Automobile, Weichai Automobile is located in the production base in Chongqing and has started construction in early 2013. The planned annual production capacity is 300,000 vehicles and the total investment is more than RMB 5 billion. Among them, the first phase of capacity planning 100,000, will be put into use early next year. At the same time, Weichai Auto's channel development strategy is focused on the "3+5+7" key markets, namely the three core markets of Shandong, Chongqing and Sichuan; five key markets are Hebei, Henan, Jiangsu, Guangdong, and Yunnan; and seven key markets In Anhui, Hunan, Guizhou, Liaoning, Shaanxi, Shanxi and Zhejiang, distribution network construction in 2013 has basically covered all key markets.
According to the information revealed in the above content, the market that Weichai Motor intends to open will surely compete with numerous car companies whose strengths are intertwined. It's hard to imagine how challenging it is to compete with the crowd.
Excess capacity, according to the national warning <br> <br> 12 major domestic car prices released "Twelfth Five-Year Plan", 2015, which produced 12 preliminary planning capacity of around 32.5 million in 2015 to China so many cars ? Can the world "digest" so many Chinese cars?
At present, with the exception of medium and large-sized passenger cars in China, there are excess capacity in heavy-duty trucks, medium-sized trucks, light trucks, mini-trucks, light-duty passenger cars and mini-buses. In particular, heavy-duty trucks and light-duty passenger vehicles continue to enter the auto industry in excess of capacity. More serious, its excess capacity has generally reached 50%. Among them, Beiqi Foton, Zhongxing Automobile, Xiamen Golden Dragon, Xiamen Golden Brigade, Fujian New Longma, Shaanxi Automobile Tongjia, SAIC Commercial Vehicle, and Jiangsu Kawei commercial vehicle companies have also joined the field of passenger cars, and have started or plan to launch products. The models with better sales of SUVs and MPVs are the main targets of these companies. The penetration of commercial vehicle passenger vehicle companies in China has become increasingly fierce.
On January 22, 2013, the Ministry of Industry and Information Technology released the “Guidance Opinions on Accelerating the Merger and Reorganization of Enterprises in Key Industriesâ€, ranking the first in the automotive industry, requiring that by 2015, the industry concentration of the top 10 vehicle manufacturers should reach 90%. Form 3-5 large-scale automobile enterprise groups with core competitiveness. Obviously, the country does not want to see the excessive development of many car companies.
At present, with the exception of medium and large-sized passenger cars in China, there are excess capacity in heavy-duty trucks, medium-sized trucks, light trucks, mini-trucks, light-duty passenger cars and mini-buses. In particular, heavy-duty trucks and light-duty passenger vehicles continue to enter the auto industry in excess of capacity. More serious, its excess capacity has generally reached 50%.
In 2013, the Ministry of Industry and Information Technology suspended the declaration of new products for 48 auto companies, which is a warning to the rapid-rising commercial vehicle companies in recent years. As the market shrinks, commercial vehicle companies will also see large-scale mergers and reorganizations.
Even so, it is still difficult for many car companies to expand their enthusiasm. In 2013, the production and sales of automobiles nationwide was 22,116,800 cars and 21.9841 million cars, which represented a year-on-year increase of 14.8% and 13.9%, respectively, and hit the world's first "happy news" for five consecutive years. It was also "fueling".
Vehicle expansion expands on June 6th, 2012 On June 6, 2012, Shanghai General Motors invested RMB 7 billion to build a 300,000-year-old automobile plant that broke ground in Jiangxia, Jinxia, ​​Wuhan. It is expected that the plant will be mass-produced in November 2014.
On May 15, 2013, Shanghai Volkswagen Changsha officially settled in Changsha Economic and Technological Development Zone. It is reported that the Changsha project will cover an area of ​​1.38 million square meters and will form a production capacity of 300,000 complete vehicles. It is expected to be completed and put into operation in 2015.
On May 26, 2013, the FAW-Volkswagen Foshan Phase II project was signed. It is expected to be completed and put into production in 2016, and will have the capacity to produce 300,000 vehicles a year. At the same time, the FAW-Volkswagen Hohhot base project has also appeared on the local People's Congress website.
On May 28, 2013, the groundbreaking ceremony of GAC Honda's third plant and engine plant was held in Zengcheng, Guangzhou. It is expected to be completed and put into operation in early 2015. The initial production capacity will be 120,000, and will be expanded to 240,000 later.
On June 19, 2013, Changan Ford Motor Co., Ltd., a new engine factory in Chongqing, was officially put into operation. Used to produce Ford high-end models as well as SUVs, crossover models and other products.
The BAIC Group's "Beiqi Automobile" strategy has established production bases in Chongqing, Guangzhou, Hunan, Hebei, Jiangxi, Jiangsu and other places through acquisition and reorganization. The models of the models produced cover a full range of products including heavy trucks, light trucks, light passengers, off-road vehicles, micro-customers, SUVs, MPVs, and CRAs.
On December 15, 2013, the Jianghuai Automobile Southwest Base Construction Project was officially signed in Suining and settled in the Suining Anju Industrial Development Zone. The construction period of the project is 3 years. The planned investment is 1.1 billion yuan. After the project is completed, it will have a production capacity of about 10 billion yuan.
On December 16, 2013, Dongfeng Motor Group Co., Ltd. and Renault will sign the signing ceremony of a joint venture contract in Wuhan, and Dongfeng Renault will be the first Chinese-made SUV model, Koreo.
In addition, Beijing No. 4 Modern Factory will be located in Chongqing’s Liangjiang New District; Dongfeng Nissan’s 300,000 factories in Dalian will also be officially completed in 2014; Dongfeng Yueda KIA will build a new plant with 300,000 capacity in Yancheng; The fourth factory has been put on the agenda, and the site is currently under construction. The new factory is expected to settle in Chengdu.
From this point of view, the Chinese automobile market in the next few years will be an unprecedented "Warring States era," and the intensity of competition will be extremely fierce. This can not be reminiscent of China's television, refrigerator factory, and finally eliminated according to market laws and regulations, a handful of powerful companies. How the latecomer Weichai Motors will compete with these climate-friendly opponents will be a long and difficult road. Empagliflozin API
Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
Empagliflozin is a C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a sodium-glucose transport protein subtype 2 inhibitor and a hypoglycemic agent. It is a C-glycosyl compound, an aromatic ether, a tetrahydrofuryl ether and a member of monochlorobenzenes.
Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; Empagliflozin (BI 10773);
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com